Welcome!

News Feed Item

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013


Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Macular Edema . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Macular Edema . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Diabetic Macular Edema 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Diabetic Macular Edema 23
Subjects Recruited Over a Period of Time 27
Prominent Sponsors 28
Top Companies Participating in Diabetic Macular Edema Therapeutics Clinical Trials 30
Prominent Drug Comparison 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Regeneron Pharmaceuticals, Inc. 38
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Bayer AG 40
Clinical Trial Overview of Bayer AG 40
Alimera Sciences, Inc. 41
Clinical Trial Overview of Alimera Sciences, Inc. 41
Santen Pharmaceutical Co., Ltd. 42
Clinical Trial Overview of Santen Pharmaceutical Co., Ltd. 42
Bausch & Lomb Incorporated 43
Clinical Trial Overview of Bausch & Lomb Incorporated 43
Clinical Trial Overview of Top Institutes / Government 44
Diabetic Retinopathy Clinical Research Network 44
Clinical Trial Overview of Diabetic Retinopathy Clinical Research Network 44
National Eye Institute 45
Clinical Trial Overview of National Eye Institute 45
Johns Hopkins University 46
Clinical Trial Overview of Johns Hopkins University 46
Shahid Beheshti University of Medical Sciences 47
Clinical Trial Overview of Shahid Beheshti University of Medical Sciences 47
The University of Sydney 48
Clinical Trial Overview of The University of Sydney 48
Moorfields Eye Hospital NHS Foundation Trust 49
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 49
Medical University of Vienna 50
Clinical Trial Overview of Medical University of Vienna 50
Hong Kong Eye Hospital 51
Clinical Trial Overview of Hong Kong Eye Hospital 51
Federal University of Sao Paulo 52
Clinical Trial Overview of Federal University of Sao Paulo 52
University of Sao Paulo 53
Clinical Trial Overview of University of Sao Paulo 53
Five Key Clinical Profiles 54
Appendix 154
Abbreviations 154
Definitions 154
Research Methodology 155
Secondary Research 155
About GlobalData 155
Contact Us 155
Disclaimer 156
Source 156



List of Tables

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries, 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries, 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries, 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries, 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase, 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Market, Global, Suspended Clinical Trials, 2013* 23
Diabetic Macular Edema Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 24
Diabetic Macular Edema Therapeutics Market, Global, Terminated Clinical Trials, 2013* 25
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 29
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 31
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 33
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013* 35
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013* 37
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2013* 38
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 39
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2013* 40
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Alimera Sciences, Inc., 2013* 41
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Santen Pharmaceutical Co., Ltd., 2013* 42
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bausch & Lomb Incorporated, 2013* 43
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Diabetic Retinopathy Clinical Research Network, 2013* 44
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2013* 45
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2013* 46
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University of Medical Sciences, 2013* 47
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2013* 48
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Moorfields Eye Hospital NHS Foundation Trust, 2013* 49
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2013* 50
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Hong Kong Eye Hospital, 2013* 51
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2013* 52
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2013* 53



List of Figures

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries (%), 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries (%), 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries (%), 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 28
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 30
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
GlobalData Methodology 155


Read the full report:
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013
http://www.reportbuyer.com/pharma_healthcare/treatments/diabetic_macular...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera MyS...
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, introduced two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a multip...
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.